San Antonio drug developer Rapamycin scores critical funding
Researchers from The Barshop Institute and the University of Texas Health Science Center at San Antonio discovered that an improved formulation of the drug Rapamycin extended the life span of rodents by mitigating the effects of age-related diseases. Rapamycin Holdings is the exclusive licensee of this technology and hopes to bring to market treatment options that could also eventually address human diseases, including cancer and cognitive disfunctions.